Analysis of Circulating Tumor DNA to Predict Neoadjuvant Therapy Effectiveness and Breast Cancer Recurrence

다국어 초록 (Multilingual Abstract)

Purpose: Real-time detection and intervention can be used as potential measures to markedly decrease breast cancer mortality. Assessment of circulating tumor DNA (ctDNA) may offer great benefits for the management of breast cancer over time. However, the use of ctDNA to predict the effectiveness of neoadjuvant treatment and recurrence of breast cancer has rarely been studied.
Methods: We prospectively recruited 31 breast cancer patients with 4 subtypes. Three time points were set in this study, including before any therapy (C1), during surgery (T), and six months after surgery (C2). We collected peripheral blood samples from all 31 patients at C1, tumor tissue from all 31 patients at T, and peripheral blood samples from 25 patients at C2. Targeted 727-gene panel sequencing was performed on ctDNA from all blood samples and tissue DNA from all tissue samples. Somatic mutations were detected and analyzed using a reference standard pipeline. Statistical analysis was performed to identify possible associations between ctDNA profiles and clinical outcomes.
Results: In total, we detected 159, 271, and 70 somatic mutations in 30 C1 samples, 31 T samples, and 12 C2 samples, respectively. We identified specific genes, such as PIK3CA, TP53, and KMT2C, which were highly mutated in the tissue samples. Furthermore, mutated KMT2C observed in ctDNA of the C2 samples may be an indicator of breast cancer recurrence.
Conclusion: Our study highlights the potential of ctDNA analysis at different timepoints for assessing tumor progression and treatment effectiveness, as well as prediction of breast cancer recurrence.

참고문헌 (Reference)

1 Koboldt DC, "VarScan 2 : somatic mutation and copy number alteration discovery in cancer by exome sequencing" 22 : 568-576, 2012

2 Niyomnaitham S, "Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene" 7 : e6501-, 2019

3 Pereira B, "The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes" 7 : 11479-, 2016

4 Silwal-Pandit L, "TP53 mutations in breast and ovarian cancer" 7 : a026252-, 2017

5 Prat A, "Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy" 13 : 303-, 2015

6 Zheng RS, "Report of cancer epidemiology in China, 2015" 41 : 19-28, 2019

7 Peng J, "RECQL5 plays an essential role in maintaining genome stability and viability of triple-negative breast cancer cells" 8 : 4743-4752, 2019

8 Coombes RC, "Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence" 25 : 4255-4263, 2019

9 Esserman LJ, "Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657" 30 : 3242-3249, 2012

10 Zhang X, "Parallel analyses of somatic mutations in plasma circulating tumor DNA(ctDNA)and matched tumor tissues in early-stage breast cancer" 25 : 6546-6553, 2019

11 Oshiro C, "PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients" 150 : 299-307, 2015

12 Loibl S, "PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2(HER2)therapy in primary HER2-overexpressing breast cancer" 32 : 3212-3220, 2014

13 do Valle ÍF, "Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data" 17 : 341-, 2016

14 Shatsky R, "Next-generation sequencing of tissue and circulating tumor DNA : the UC San Diego Moores Center for personalized cancer therapy experience with breast malignancies" 18 : 1001-1011, 2019

15 Kandoth C, "Mutational landscape and significance across 12 major cancer types" 502 : 333-339, 2013

16 Peng Sun, "Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast" Springer Science and Business Media LLC 33 (33): 1945-1960, 2020

17 Haddad TC, "Landscape of neoadjuvant therapy for breast cancer" 22 : 1408-1415, 2015

18 Gala K, "KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function" 37 : 4692-4710, 2018

19 Fan Z, "Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients" 169 : 59-67, 2018

20 Bhaskaran SP, "Germline variation in BRCA1/2 is highly ethnic-specific: evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients" 145 : 962-973, 2019

21 Bertucci F, "Genomic characterization of metastatic breast cancers" 569 : 560-564, 2019

22 Food and Drug Administration, "FDA approves alpelisib for metastatic breast cancer"

23 Yap YS, "Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers" 4 : 19-, 2018

24 Ren S, "Efficient acceleration of the pair-HMMs forward algorithm for GATK HaplotypeCaller on graphics processing units" 14 : 2018

25 Cancer Genome Atlas Network, "Comprehensive molecular portraits of human breast tumours" 490 : 61-70, 2012

26 Weiss NS, "Cohort studies of the efficacy of screening for cancer" 26 : 362-364, 2015

27 Jian W, "Clinical and genetic characterization of hereditary breast cancer in a Chinese population" 15 : 19-, 2017

28 Buono G, "Circulating tumor DNA analysis in breast cancer : is it ready for prime-time" 73 : 73-83, 2019

29 Dai X, "Breast cancer intrinsic subtype classification, clinical use and future trends" 5 : 2929-2943, 2015

30 Copur MS, "Alpelisib for PIK3CA-mutated advanced breast cancer" 381 : 686-687, 2019